3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Gastrointestinal
1
Conditions
Breast Neoplasms
547
Carcinoma, Non-Small-Cell Lung
506
Prostatic Neoplasms
332
Colorectal Neoplasms
270
Multiple Myeloma
266
Neoplasms
260
Leukemia, Myeloid, Acute
221
Squamous Cell Carcinoma of Head and Neck
213
Lung Neoplasms
206
Neoplasm Metastasis
203
Carcinoma, Hepatocellular
196
Melanoma
172
Triple Negative Breast Neoplasms
171
Pancreatic Neoplasms
170
Recurrence
152
Ovarian Neoplasms
149
Lymphoma
139
Brain Neoplasms
132
Glioblastoma
131
Sarcoma
130
Carcinoma, Renal Cell
126
Leukemia, Lymphocytic, Chronic, B-Cell
124
Head and Neck Neoplasms
124
Stomach Neoplasms
122
Lymphoma, Large B-Cell, Diffuse
122
Rectal Neoplasms
107
Precursor Cell Lymphoblastic Leukemia-Lymphoma
105
Myelodysplastic Syndromes
102
Uterine Cervical Neoplasms
100
Urinary Bladder Neoplasms
100
Interventions
relatlimab
1
daratumumab
1
cobimetinib
1
Nivolumab
1
Ipilimumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Microsatellite Unstable Colorectal Cancer
×
1 year
×
Clear all
NCT02060188
2025-11-06
CheckMate142
Bristol-Myers Squibb
Phase 2
Completed
385 enrolled
17 charts
2 FDA